Cargando…

Determinants of Thyrotoxic Cardiomyopathy Recovery

The purpose was to evaluate the effect of the disease duration prior to treatment, thyroid hormones level, or both on the reversibility of dilated cardiomyopathy. Between January 2006 and December 2010, a longitudinal study with a 6 months follow-up was carried on. One hundred and seventy patients w...

Descripción completa

Detalles Bibliográficos
Autores principales: Oliveros-Ruiz, Lucia, Vallejo, Maite, Diez Canseco, L. Fernando, Cárdenas, Manuel, Hermosillo, J. Antonio G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3780617/
https://www.ncbi.nlm.nih.gov/pubmed/24106705
http://dx.doi.org/10.1155/2013/452709
_version_ 1782285322777788416
author Oliveros-Ruiz, Lucia
Vallejo, Maite
Diez Canseco, L. Fernando
Cárdenas, Manuel
Hermosillo, J. Antonio G.
author_facet Oliveros-Ruiz, Lucia
Vallejo, Maite
Diez Canseco, L. Fernando
Cárdenas, Manuel
Hermosillo, J. Antonio G.
author_sort Oliveros-Ruiz, Lucia
collection PubMed
description The purpose was to evaluate the effect of the disease duration prior to treatment, thyroid hormones level, or both on the reversibility of dilated cardiomyopathy. Between January 2006 and December 2010, a longitudinal study with a 6 months follow-up was carried on. One hundred and seventy patients with hyperthyroidism were referred to the cardiologist, and 127 had a 6 months followup after antithyroid treatment and were evaluated by echocardiography. Dilated cardiomyopathy reversibility criteria were established according to echocardiographic parameters. Complete reversibility existed when all parameters were met, partial reversibility when LVEF was ≥55% plus two or three other parameters, and no reversibility when LVEF was ≤55% regardless of other parameters. The results showed that echocardiography parameters related to the regression of myocardial mass were associated with a disease duration shorter than 10.38 months. This was the main predictive variable for reversal of dilated cardiomyopathy, followed by β-blocker treatment, and the last predictive variable was the serum level of free triiodothyronine. This study showed that the effect on the myocardium related to thyrotoxicosis was associated with the disease duration before treatment.
format Online
Article
Text
id pubmed-3780617
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-37806172013-10-08 Determinants of Thyrotoxic Cardiomyopathy Recovery Oliveros-Ruiz, Lucia Vallejo, Maite Diez Canseco, L. Fernando Cárdenas, Manuel Hermosillo, J. Antonio G. Biomed Res Int Clinical Study The purpose was to evaluate the effect of the disease duration prior to treatment, thyroid hormones level, or both on the reversibility of dilated cardiomyopathy. Between January 2006 and December 2010, a longitudinal study with a 6 months follow-up was carried on. One hundred and seventy patients with hyperthyroidism were referred to the cardiologist, and 127 had a 6 months followup after antithyroid treatment and were evaluated by echocardiography. Dilated cardiomyopathy reversibility criteria were established according to echocardiographic parameters. Complete reversibility existed when all parameters were met, partial reversibility when LVEF was ≥55% plus two or three other parameters, and no reversibility when LVEF was ≤55% regardless of other parameters. The results showed that echocardiography parameters related to the regression of myocardial mass were associated with a disease duration shorter than 10.38 months. This was the main predictive variable for reversal of dilated cardiomyopathy, followed by β-blocker treatment, and the last predictive variable was the serum level of free triiodothyronine. This study showed that the effect on the myocardium related to thyrotoxicosis was associated with the disease duration before treatment. Hindawi Publishing Corporation 2013 2013-09-08 /pmc/articles/PMC3780617/ /pubmed/24106705 http://dx.doi.org/10.1155/2013/452709 Text en Copyright © 2013 Lucia Oliveros-Ruiz et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Oliveros-Ruiz, Lucia
Vallejo, Maite
Diez Canseco, L. Fernando
Cárdenas, Manuel
Hermosillo, J. Antonio G.
Determinants of Thyrotoxic Cardiomyopathy Recovery
title Determinants of Thyrotoxic Cardiomyopathy Recovery
title_full Determinants of Thyrotoxic Cardiomyopathy Recovery
title_fullStr Determinants of Thyrotoxic Cardiomyopathy Recovery
title_full_unstemmed Determinants of Thyrotoxic Cardiomyopathy Recovery
title_short Determinants of Thyrotoxic Cardiomyopathy Recovery
title_sort determinants of thyrotoxic cardiomyopathy recovery
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3780617/
https://www.ncbi.nlm.nih.gov/pubmed/24106705
http://dx.doi.org/10.1155/2013/452709
work_keys_str_mv AT oliverosruizlucia determinantsofthyrotoxiccardiomyopathyrecovery
AT vallejomaite determinantsofthyrotoxiccardiomyopathyrecovery
AT diezcansecolfernando determinantsofthyrotoxiccardiomyopathyrecovery
AT cardenasmanuel determinantsofthyrotoxiccardiomyopathyrecovery
AT hermosillojantoniog determinantsofthyrotoxiccardiomyopathyrecovery